In the news

The CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line option for stroke risk reduction met all primary and secondary endpoints and demonstrated superior bleeding risk reduction and similar efficacy of the WATCHMAN FLX device compared to oral anticoagulants in a broad population of patients with non-valvular atrial fibrillation.

Learn how findings from the HI-PEITHO trial highlight a major advance in the treatment of immediate-risk pulmonary embolism, with ultrasound-assisted, catheter-directed thrombolysis using the EKOS™ Endovascular System reducing early complications without increasing major bleeding.

Driven by an improved safety profile, strong patient demand and more predictable procedures, health systems are increasing investment in pulsed field ablation (PFA)—including technology like the FARAPULSE™ PFA Platform—to treat atrial fibrillation.

Read how Boston Scientific designed its latest employee campus with an intentional focus on collaboration for rapid innovation in this interview with Stephanie Board, group vice president, Research & Development, Interventional Cardiology & Vascular Therapies.

Learn how Boston Scientific consistently achieved superior results while minimizing distressing organizational transformations by creating and continually cultivating the business equivalent of a thriving, adaptive biological ecosystem.